Berenberg raises target for BioNTech stock from USD 132 to USD 140

Published on 10/05/2026 at 09:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Gotistobart delivered 18.50 versus 10.00 months median survival. BioNTech stock costs EUR 86.03 on October 5, 2026 versus EUR 86.10.

BioNTech SE, US09075V1026, Illustration mit AI erstellt.

BioNTech SE (ISIN US09075V1026) has a USD 140.00 Berenberg target after a rise from USD 132.00. According to MarketScreener on September 16, 2026, Berenberg kept a Buy rating while raising its target. BioNTech stock was trading at EUR 86.03 at Lang & Schwarz on October 5, 2026.

Oncology data strengthens the case

The target increase arrived after BioNTech and OncoC4 reported updated gotistobart data in previously treated squamous non-small cell lung cancer. FinanzNachrichten reported on September 14, 2026, that median overall survival reached 18.50 months with gotistobart, versus 10.00 months with docetaxel.

That is an 85.00 percent improvement against the chemotherapy comparison. The result came from stage 1 of the PRESERVE-003 Phase 3 trial, while the pivotal stage 2 portion was ongoing across more than 160 sites.

Cash and quarterly losses matter

BioNTech's second-quarter 2026 revenue was USD 145.80 million, while its consolidated net loss was USD 820.80 million, according to the periodized financial data. The figures show why clinical progress and commercial conversion remain separate questions for the oncology transition.

The company describes its pipeline as spanning immunomodulators, antibody drug conjugates and mRNA cancer immunotherapies. Its investor page also lists partnerships with Pfizer, Bristol Myers Squibb, Genentech, Genmab, MediLink and OncoC4, giving the development strategy a broad collaboration base.

Results date sets the next test

BioNTech is scheduled to release third-quarter 2026 results on November 2, 2026, according to MarketScreener. That report will put the USD 140.00 target against a newer operating update and may clarify how quickly the research pipeline can offset pressure from the declining COVID-19 product business.

BioNTech stock holds near prior close

The Lang & Schwarz quote was EUR 86.03 on October 5, 2026 at 9:03 a.m. CEST, down 0.08 percent versus the prior close of EUR 86.10 on October 2, 2026. The Nasdaq-listed ADR had a USD 24.3 billion market capitalization and a USD 79.52 to USD 124.00 52-week range as of October 2, 2026.

The further course of trading is shown by the continuously updated real-time quote of BioNTech stock.